HCAT

Health Catalyst, Inc. (HCAT) - Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers the unaudited quarterly report on Form 10-Q for Health Catalyst, Inc. for the period ended March 31, 2026. Health Catalyst is a provider of data and analytics technology and services to healthcare organizations. The company operates in two segments: Technology (cloud-based data platform and analytics applications) and Professional Services (analytics, implementation, and advisory services).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 11% year-over-year. Technology revenue fell 4% due to churn and down-sells related to the migration from the legacy DOS platform to Health Catalyst Ignite. Professional services revenue dropped 24% due to the exit of lower-margin Tech-enabled Managed Services (TEMS) arrangements and FTE churn.
• Significant Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $95.5 million in Q1 2026. This was triggered by declines in stock price and market capitalization, which reduced the fair value of the Technology reporting unit below its carrying value. No such charge occurred in Q1 2025.
• Operating Expense Reduction: Despite the impairment charge, operating expenses excluding impairment decreased significantly. Sales and marketing expenses dropped 28%, and R&D expenses fell 36%, primarily due to restructuring activities and reduced headcount.
• Improved Operating Cash Flow: Net cash provided by operating activities improved to $18.5 million from $0.3 million in the prior year, driven by strong collections and cost reductions, despite the net loss.

Outlook, Risks, and Unusual Items

• Strategic Migration (DOS to Ignite): The company is actively migrating clients from its legacy DOS platform to Health Catalyst Ignite. This process has caused revenue headwinds, with $12.5 million in ARR down-sell/churn notified and an estimated $52.0 million in at-risk ARR. Management expects to be generally through migrations by the end of 2027.
• Project Nexus: In a subsequent event (April 2026), the Board authorized "Project Nexus," a workforce reduction expected to cut approximately 9% of the global workforce in Q2 2026. The company anticipates incurring at least $4.0 million in charges related to this initiative.
• Macroeconomic Pressures: The company cites high inflation, interest rates, and cuts to Medicaid and research funding (specifically the OBBBA legislation) as factors elongating sales cycles and straining client budgets.
• Debt Covenants: The company maintains a credit agreement with a term loan facility. As of March 31, 2026, it was in compliance with all covenants, including minimum liquidity and leverage ratios.

Investor Verification Checklist

• Goodwill Impairment Sustainability: Verify if the $95.5 million impairment is a one-time event or if further declines in stock price could trigger additional charges in future quarters.
• Migration Retention Rates: Monitor the success of the DOS to Ignite migration strategy and the actual realization of the $52.0 million at-risk ARR.
• Project Nexus Impact: Assess the financial impact of the Q2 2026 workforce reduction and whether it achieves the targeted cost structure optimization.
• Client Concentration: Review the top three clients, which comprised 13.6% of 2025 revenue, for any signs of churn or contract renegotiation.
• Liquidity Position: Confirm that the $108.8 million in cash and short-term investments is sufficient to cover debt service and operational needs given the ongoing restructuring costs.